N
ACAD icon

Nuveen’s Acadia Pharmaceuticals ACAD Stock Holding History

Nuveen’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-51,500
Closed -$1K – 3351
2021
Q1 		$1K Buy
+51,500
New +$2.27M ﹤0.01% 3358
2020
Q4 		– Sell
-61,200
Closed -$3K – 3303
2020
Q3 		$3K Buy
+61,200
New +$2.64M ﹤0.01% 3277

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Nuveen's ACAD Position: Q1 2026 in Review

Nuveen reduced its Acadia Pharmaceuticals (ACAD) stake by 1.9% in Q1 2026, selling an estimated $491K and leaving 1,036,987 shares worth $23.1M. The position accounts for 0.01% of the portfolio, ranked #1051.

Nuveen first reported a position in ACAD in Q4 2013 and has held it in 33 quarters since. The position peaked at $94M in Q4 2019. 342 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Nuveen held 1,036,987 shares of Acadia Pharmaceuticals worth $23.1M as of Q1 2026.
  • Nuveen sold 20,540 Acadia Pharmaceuticals shares in Q1 2026, an estimated $491K.
  • Acadia Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q1 2026, its #1051 holding.
  • Nuveen first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 33 quarters since.
  • Nuveen's Acadia Pharmaceuticals position peaked at $94M in Q4 2019.
  • 342 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.